Arcus Biosciences

Creating Innovative Cancer Immunotherapies

Learn more about us

Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

Learn more

Press Releases

May 9, 2018 in Press Releases

Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates

Read More
April 17, 2018 in Press Releases

Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting

Read More
March 19, 2018 in Press Releases

Arcus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More

Pipeline

AB928

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.

AB154

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.

AB122

AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.

AB680

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.

Go to Pipeline

Arcus has approximately 75 employees with significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership